872 related articles for article (PubMed ID: 11991752)
41. Intracerebral versus subcutaneous immunization with allogeneic fibroblasts genetically engineered to secrete interleukin-2 in the treatment of central nervous system glioma and melanoma.
Glick RP; Lichtor T; Mogharbel A; Taylor CA; Cohen EP
Neurosurgery; 1997 Oct; 41(4):898-906; discussion 906-7. PubMed ID: 9316052
[TBL] [Abstract][Full Text] [Related]
42. Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100.
Xia DJ; Zhang WP; Zheng S; Wang J; Pan JP; Wang Q; Zhang LH; Hamada H; Cao X
Gene Ther; 2002 May; 9(9):592-601. PubMed ID: 11973635
[TBL] [Abstract][Full Text] [Related]
43. Vaccination with IL-18 gene-modified, superantigen-coated tumor cells elicits potent antitumor immune response.
Wang Q; Yu H; Zhang L; Ju D; Pan J; Xia D; He L; Wang J; Cao X
J Cancer Res Clin Oncol; 2001 Dec; 127(12):718-26. PubMed ID: 11768611
[TBL] [Abstract][Full Text] [Related]
44. Generation of tumor-specific cytotoxic T lymphocytes in vivo by combined treatment with inactivated tumor cells and recombinant interleukin-2.
Harada M; Matsuzaki G; Shinomiya Y; Kurosawa S; Ito O; Okamoto T; Takenoyama M; Sumitika H; Nishimura Y; Nomoto K
Cancer Immunol Immunother; 1994 May; 38(5):332-8. PubMed ID: 8162615
[TBL] [Abstract][Full Text] [Related]
45. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
[TBL] [Abstract][Full Text] [Related]
46. Sensitizing T-lymphocytes for adoptive immunotherapy by vaccination with wild-type or cytokine gene-transduced melanoma.
Lipshy KA; Kostuchenko PJ; Hamad GG; Bland CE; Barrett SK; Bear HD
Ann Surg Oncol; 1997 Jun; 4(4):334-41. PubMed ID: 9181234
[TBL] [Abstract][Full Text] [Related]
47. Therapeutic effect of pEgr-IL18-B7.2 gene radiotherapy in B16 melanoma-bearing mice.
Yang J; Jin G; Liu X; Liu S
Hum Gene Ther; 2007 Apr; 18(4):323-32. PubMed ID: 17411412
[TBL] [Abstract][Full Text] [Related]
48. A new mouse model of experimental melanoma for vaccine and lymphokine therapy.
Shrayer DP; Bogaars H; Wolf SF; Hearing VJ; Wanebo HJ
Int J Oncol; 1998 Aug; 13(2):361-74. PubMed ID: 9664134
[TBL] [Abstract][Full Text] [Related]
49. Enhanced antitumor response mediated by the codelivery of paclitaxel and adenoviral vector expressing IL-12.
Cao L; Zeng Q; Xu C; Shi S; Zhang Z; Sun X
Mol Pharm; 2013 May; 10(5):1804-14. PubMed ID: 23534449
[TBL] [Abstract][Full Text] [Related]
50. IL-12 gene therapy using an electrically mediated nonviral approach reduces metastatic growth of melanoma.
Lucas ML; Heller R
DNA Cell Biol; 2003 Dec; 22(12):755-63. PubMed ID: 14683586
[TBL] [Abstract][Full Text] [Related]
51. Application of interleukin 12 to antitumor cytokine and gene therapy.
Nishimura T; Watanabe K; Yahata T; Ushaku L; Ando K; Kimura M; Saiki I; Uede T; Habu S
Cancer Chemother Pharmacol; 1996; 38 Suppl():S27-34. PubMed ID: 8765412
[TBL] [Abstract][Full Text] [Related]
52. Antimetastatic vaccination against Lewis lung carcinoma with autologous tumor cells modified to express murine interleukin 12.
Popovic D; El-Shami KM; Vadai E; Feldman M; Tzehoval E; Eisenbach L
Clin Exp Metastasis; 1998 Oct; 16(7):623-32. PubMed ID: 9932609
[TBL] [Abstract][Full Text] [Related]
53. Archaeosomes induce enhanced cytotoxic T lymphocyte responses to entrapped soluble protein in the absence of interleukin 12 and protect against tumor challenge.
Krishnan L; Sad S; Patel GB; Sprott GD
Cancer Res; 2003 May; 63(10):2526-34. PubMed ID: 12750276
[TBL] [Abstract][Full Text] [Related]
54. IL-12 gene therapy is an effective therapeutic strategy for hepatocellular carcinoma in immunosuppressed mice.
Harada N; Shimada M; Okano S; Suehiro T; Soejima Y; Tomita Y; Maehara Y
J Immunol; 2004 Dec; 173(11):6635-44. PubMed ID: 15557154
[TBL] [Abstract][Full Text] [Related]
55. Gene transfer of secreted-type modified interleukin-18 gene to B16F10 melanoma cells suppresses in vivo tumor growth through inhibition of tumor vessel formation.
Nagai H; Hara I; Horikawa T; Oka M; Kamidono S; Ichihashi M
J Invest Dermatol; 2002 Sep; 119(3):541-8. PubMed ID: 12230493
[TBL] [Abstract][Full Text] [Related]
56. Vaccination using melanoma cells treated with p19arf and interferon beta gene transfer in a mouse model: a novel combination for cancer immunotherapy.
Medrano RF; Catani JP; Ribeiro AH; Tomaz SL; Merkel CA; Costanzi-Strauss E; Strauss BE
Cancer Immunol Immunother; 2016 Apr; 65(4):371-82. PubMed ID: 26887933
[TBL] [Abstract][Full Text] [Related]
57. Enhancement of antitumor immunity against B16 melanoma tumor using genetically modified dendritic cells to produce cytokines.
Akiyama Y; Watanabe M; Maruyama K; Ruscetti FW; Wiltrout RH; Yamaguchi K
Gene Ther; 2000 Dec; 7(24):2113-21. PubMed ID: 11223993
[TBL] [Abstract][Full Text] [Related]
58. Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon gamma.
Pulaski BA; Clements VK; Pipeling MR; Ostrand-Rosenberg S
Cancer Immunol Immunother; 2000 Apr; 49(1):34-45. PubMed ID: 10782864
[TBL] [Abstract][Full Text] [Related]
59. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.
van Elsas A; Hurwitz AA; Allison JP
J Exp Med; 1999 Aug; 190(3):355-66. PubMed ID: 10430624
[TBL] [Abstract][Full Text] [Related]
60. Intratumoral IL-18 gene transfer improves therapeutic efficacy of antibody-targeted superantigen in established murine melanoma.
Wang Q; Yu H; Ju DW; He L; Pan JP; Xia DJ; Zhang LH; Cao X
Gene Ther; 2001 Apr; 8(7):542-50. PubMed ID: 11319621
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]